VEGFA and renal cell carcinoma: Given the profound effects of VEGF inhibition in the tumour microenvironment beyond vascular remodelling, combinations of VEGF-targeting agents and checkpoint inhibitors have rapidly advanced from phase I to III clinical trials with noteworthy early results in renal cell carcinoma and non-small-cell lung cancer (53).